responsible business supplement success depend ability research develop innovative product accessible people responsible waygsk responsible business supplement supplement learn embed responsible business practice business report key information approach responsible business alongside financial performance annual report supplementary document provide additional context detail progress responsible business commitment cover image nadeen debbie lindsay weybridge lab work reformulation chlorhexidine solution corsodyl mouthwash antiseptic gel help prevent umbilical cord infection develop country guide report guide navigation button dynamic link screen mode interactive pdf design help click dynamic link access pdf set view screen mode easily navigate report find main content relevant information report online exit screen mode press escape view information look use tab toolbar search pdf navigate section printerfriendly pdf use print icon navigation print print document printfriendly format precede return visitedgsk responsible business supplement content inside report approach health behaviour people planet datum summary learn ensure find read learn create find manage read key datum business operate develop innovative product embed value inspire supportive work environmental impact responsibly improve access business environment encourage operation product healthcare patient include way employee develop life cycle reduce world research develop sell capability achieve carbon emission water use market product good waste chairmans statement approach approach approach approach datum summary ceo statement innovation unmet ethical conduct develop people understand summary medical need inspire healthy value chain carbon footprint assurance statement performance highlight promote value sale workplace well access medicine marketing practice aim carbon neutral responsible business vaccine promote inclusion practice transparency reduce water impact diversity building product well clinical trial datum progress commitment reduce waste meet need community volunteer rigorous patient create change reduce child mortality consumer safety strengthen healthcare minimise animal testing infrastructure promote human right eliminate control ensure ethical interaction neglect tropical disease approach tax fighting malaria work party eradicate polio access antiretroviral treatment hiv gsk responsible business supplement chairman statement operate responsibly fundamental gsk strong performance responsible group strategy chairman business evident company high external benchmarking witness significant stride ranking external benchmarking exercise gsk make promote innovation improve gsk top access medicine index gsk top access access healthcare challenge industry inception maintain position medicine index norm issue sale practice dow jones sustainability index fourth consecutive time longstanding member ftsegood biennial assessment board aim reinforce support begin management commitment operate ethically company effort reduce environmental responsibly worldwide board impact recognise corporate responsibility committee crc score carbon disclosure include dow oversee policy programme cdp reflect extensive reporting gsk jones sustainability world business ensure company take manage risk opportunity associate index score action interest society climate change approach manage economic environmental shareholder nonexecutive water impact acknowledge social performance director lynn elsenhans take chair score cdp water index crc follow sir christopher gents improve score information group responsible retirement board secure business approach performance detailed place cdps ftse topic issue annual report responsible business climate disclosure crc review company commitment supplement provide detail leadership index operate transparently integrity material social environmental topic eighth consecutive year transformation commercial set progress recognition quality model explore critical issue commitment disclosure climate balance need return investment continue welcome dialogue change impact innovation need price product company stakeholder matter relate appropriately improve access patient supplement gsk continue pharmaceutical company hold carbon trust rer carbon standard cut carbon emission water standard reduce water use philip hampton operation globally chairman member ftsegood gsk responsible business supplement ceo statement whilst year substantial increase attention whilst absolute carbon footprint change gsk remain fully price medicine notably usa increase year reduce focusse progress responsible seek price medicine vaccine value chain carbon footprint product business commitment responsibly sustainably reflect ship average compare proactive measure new way value deliver patient healthcare reduce direct carbon work healthcare professional system wide society customer emission extend respond societys ability pay tiere pricing approach access product particularly propellant press health need like ebola vaccine commitment price medicine base inhaler reduce environmental develop country impact value chain increasingly gsk malaria candidate vaccine product european price strong example challenging continue look way year research receive positive approach develop market continue minimise impact scientific opinion european regulator seek flexible approach pricing look year use prevention malaria young give significant level restructuring opportunity price accord value child subsaharan africa group seek provide support usa recently launch important step make vaccine leave company invest medicine price parity discount available alongside tool protect listen employee global staff survey medicine aim supercede child malaria provide participation rate year score vaccine notforprofit price ensure january complete roll measure empowerment resilience price barrier access new compensation model sale team score employee engagement january stop pay doctor understandably fall senior leader partnership save child achieve speak behalf instead engage group take step address major milestone submit approval digital channel provide direct antiseptic gel prevent potentially fatal conclusion like thank contact medical team umbilical cord infection newborn develop employee partner continue hard change step high expectation country accelerate development work support goal responsible society healthcare company candidate vaccine ebola response business effort support improve performance outbreak west africa provide able achieve year humanitarian support region affect clear expectation ethical conduct people strengthen see increase focus antibiotic resistance code conduct training increase relevance spite scientific challenge area different culture maintain global gsk active pipeline include standard remain vigilant aware potential new firstinclass treatment complex risk factor market move phase iii development operate fulfil commitment take collaborative approach research sir andrew witty want work government create clinical trial transparency year chief executive officer inception clinical trial database list new economic model help secure trial research team new supply antibiotic future give access detailed trial datagsk responsible business supplement approach performance highlight global healthcare company big contribution society fight malaria transparency clinical trial datum carbon innovate drive access medicine european medicine agency adopt research team give access reduce direct carbon emission vaccine consumer healthcare product positive scientific opinion malaria gsk trial datum scope save seek bring health benefit candidate vaccine mosquirix child million tonne coe year people world open aged week month flexible collaborative approach read break barrier effective healthcare opening innovation process accelerate drug discovery area great read unmet medical need scientific challenge increase access hiv medication read work address infectious grant royaltyfree voluntary licence non communicable disease continue enable generic manufacturer sell hiv increase transparency medicine significantly reduce price water work urgent public health emergency rank transparent zika ebola virus whilst ftse company transparency hit water target year early work global community prevent read international corporate political reducing usage quickly control future disease outbreak engagement index bring new vaccine medicine reduce child mortality read patient bring partner partnership save create new delivery model flexible pricing child reach million strategy increase access product child lifesave immunisation ethical conduct read treatment intervention january long pay hcp speak prescriber medicine vaccine waste produce waste read versus read engagement employee tackle antibiotic resistance workforce take global employee advance antibiotic asset survey provide valuable feedback read move phase iii study follow positive phase result read read approach responsible business practice value strong governance create value society shareholder mission help people feel stakeholder dialogue well live long research inform approach develop medicine vaccine improve people live work product available affordable people need matter live afford invest adopt flexible approach pricing promote open innovation strengthen healthcare system grow business extend access medicine ensure long term commercial success improve people health creating value shareholder deliver economic benefit wide society gsk contribute directly indirectly economic growth country tax charitable support employment people world operate responsibly support ability attract retain talent manage cost build trust patient consumer low medium customer payer stakeholder influence license operate listen stakeholder welcome engagement range respond stakeholder expectation key area identify process external stakeholder well understand year fundamentally considerable financial operational expectation societal trend team change way operate transform reputational impact business gsk regularly engage stakeholder sale marketing practice show diagram exchange customer supplier promote open innovation encourage materiality analysis review validate partner investor research unmet need annually engagement stakeholder formal engagement patient advocacy identify priority detailed description materiality analysis group policymaker identify responsible business priority available process help prioritise listen respond employee undertake formal materiality analysis effort issue matter critical help run business base importance issue business stakeholder effectively retain talented people stakeholder relevance business goal internal external input sredlohekat ecnatropmi hgih gsk responsible business supplement prioritise material issue access healthcare ethical conduct transparency product innovation clinical trial conduct responsible sale marketing intellectual property right lobbying advocacy practice product safety quality energy climate change tax community investment diversity inclusion economic animal research anticounterfeite contribution training development waste recycling privacy datum security water use human right labour ethical supplier standard talent attraction reward health safety wellbee biodiversity security supply importance business success responsible business commitment align material issue gsk responsible business supplement approach responsible business practice commitment governance conduct establish longterm responsible boardlevel corporate responsibility governance structure system business commitment sit committee crc oversee responsible key focus area health behaviour business activity meet time year board people planet table provide highlevel guidance review chairman executive director independent follow show link performance commitment nonexecutive director material issue chairman ceo member nonexecutive director lynn elsenhans regularly review responsible business longstanding member crc take commitment response stakeholder chair sir christopher gent retire feedback business strategy evolve board review result new commitment ethical conduct management key nonfinancial risk corporate corporate administration work party update govern audit risk committee audit risk remuneration nomination responsibility finance transaction commitment access antiretroviral treatment audit assurance team supports committee committee committee committee committee committee hiv subsume commitment committee provide independent view develop vaccine need keep cold board senior management wide goal build product well risk manage business meet people need long consistent agree assurance plan commitment build sustainable supply line value integrity transparency focus nutrition portfolio instead tackle patient respect people leader environmental impact product range motivate employee core value exist commitment carbon heart decision making apply water waste gsk work substantially reduce carbon emission role conduct clinical horlick report summarise progress research sell medicine interact commitment patient doctor government employee complete code conduct training annually ensure understand integrate value everyday work encourage report concern behaviour go value speak channel expect supplier party work share value set public policy statement work partiescommitment progress commitment progress progress link gsk tracker material issue lla rof htlaeh gsk responsible business supplement user key work need track progressing complete innovation unmet medical need create world open lab noncommunicable disease africa access healthcare adapt open innovation model currently disease develop appoint independent scientific advisory board select research project product innovation world apply area great unmet medical need scientific challenge accelerate development new antibiotic advance asset develop transparency include infectious disease alzheimer disease partnership move phase iii development collaborative approach dementia intellectual property right research support scientific partnership novel funding mechanism accelerate research project well access medicine vaccine partner desano pharmaceutical enable production hiv treatment access healthcare embe flexible pricing strategy innovative business model china number develop country extend price freeze commitment community investment prescription medicine vaccine increase usage able year country graduate gavi support pricing access afford product recently launch new medicine usa parity discount medicine aim supercede building product well meet need begin clinical trial heatstable lowcost inhale form oxytocin develop access healthcare continue build core range product format well meet need collaboration monash university partner submit regulatory application product innovation people globe include able access afford product european medicine agency ema antiseptic gel prevent umbilical cord infection newborn base chlorhexidine solution corsodyl mouthwash reduce child mortality partnership save child reach million access healthcare continue invest innovative crosssector partnership reduce child mortality child world poor country reward sustainable scalable healthcare innovation improve underfive child survival rate annual million healthcare innovation award strengthen healthcare infrastructure continue reinvest ldc profit country train additional access healthcare continue work partner support strengthen healthcare frontline health worker reach people million community investment infrastructure anticipate improve access healthcare million expand health worker training ldc country subsaharan africa underserve people eliminate control ntds reach million people million albendazole tablet eliminate access healthcare help eliminate control neglect tropical disease affect billion lymphatic filariasis control intestinal worm publish data highquality hit community investment people include elimination lymphatic filariasis neglect tropical disease screen million compound continue investment ongoing product donation contribution collection london declaration neglect tropical disease fight malaria receive positive scientific opinion european medicines agency malaria access healthcare build year commitment contribute fight malaria candidate vaccine rtss child age week month launch new product innovation continue investment partnership ground million partnership comic relief fight malaria endemic countriescommitment progress continue commitment progress progress link gsk tracker material issue lla rof htlaeh eradicate polio deliver million dose oral polio vaccine access healthcare continue support objective eradicating polio provide contribute billion dose invest inactivated polio vaccine facility belgium vaccine unicef achieve access antiretroviral treatment hiv reach country worldwide viiv healthcare access programme access healthcare viiv healthcare continue research new treatment increase grant royaltyfree voluntary licence enable generic manufacturer sell product innovation access medicine care people live hiv world viiv healthcare product significantly reduce price clinton support unaid deliver ambition health access initiative enable pharmaceutical company aurobindo file work community combat stigma discrimination associate hiv application fda generic approval dolutegravir ruoivaheb ruo gsk responsible business supplement user key work need track progressing complete ethical conduct employee complete mandatory annual training code conduct ethical conduct continue strengthen value base culture training people extend training complementary worker strengthen training standard expect encourage report concern embed external certification member ethic compliance team value way measure employee performance promote value sale marketing complete global rollout change sale team compensation long pay ethical conduct continue drive valuebase approach sale marketing practice healthcare professional speak prescriber medicine responsible sale world interest consumer patient core marketing transparency clinical research wellcome trust take management panel external independent expert transparency clinical transparent possible clinical trial datum include publish review proposal access datum wwwclinicalstudydatarequestcom important trial datum clinical study report patientlevel datum outcome trial medicine step create independent datasharing system include study intellectual property right conduct gsk appropriate process make available industry academia meet commitment available researcher access anonymised patient level datum scientific enquiry global study go formation gsk study rigorous patient consumer safety recognise collaboration informatic company epidemico monitor publicly anticounterfeite continue ensure interest safety patient consumer paramount available information social medium gain insight adverse effect medicine product safety quality importance way design undertake clinical trial product quality extend supply chain serialisation programme fingerprint packaging line assurance monitoring report adverse event ongoing product usage verify product supply chain help combat counterfeit minimise animal testing few animal continuation downward trend year animal research rigorously challenge need animal study work minimise impact animal rodent animal welfare invest development alternative study share animal base datum commitment update previous commitment end commitment progress continue commitment progress progress link gsk tracker material issue ruoivaheb ruo promote human right labour right include comprehensive new programme strengthen management human right labour address guiding principle business human right party risk supply chain live wage accredit employer operation supplier relationship ensure ethical interaction rank transparent ftse company transparency ethical conduct demonstrate gsk interaction patient advocacy group political international corporate political engagement index produce new global lobbying advocacy stakeholder conduct appropriately ethically transparently standard interaction patient organisation practice tax economic contribution work party introduce comprehensive new programme strengthen management party ethical conduct seek work party share commitment high ethical risk supply chain identify highrisk supplier undergo human right labour standard operate responsible way performance gap identify assessment responsible business policy practice assess appropriate commit work party improve performance highrisk distributor elpoep ruo create inspire healthy workplace employee share view employee survey response health safety continue create work environment inspire people grow perform rate refresh simplified health safety standard exceed graduate wellbee healthy resilient way recruitment target hire graduate postgraduate future leader train development esprit programme globally promote inclusion diversity welcome woman accelerate difference programme support diversity inclusion continue promote inclusion diversity globally gsk career advancement female leader partner government disability confident campaign raise disability awareness company community volunteering create change enable employee country provide million worth skilled community investment extend volunteering opportunity bring positive change community service nonprofit partner pulse volunteer programme global health provide individual development participant line manager colleague agree experience help develop skill performance tenalp ruo gsk responsible business supplement user key work need track progressing complete carbon value chain carbon footprint grow largely continued growth sale energy use climate reduce overall carbon footprint carbon propellantbase inhaler direct carbon emission decline bring total change neutral value chain reduction year score environment disclosure cdp water hit water target year early reduce usage save water use reduce water impact value chain million water use year partner energy resource institute develop water save initiative rural indian community waste produce waste compare previous year waste recycling reduce operational waste manufacturing site achieve zero waste landfill gsk responsible business supplement ealth positive action programme target key affect population reach great risk hiv infection image courtesy international centre research womengsk responsible business supplement health approach medicine vaccine consumer health highlight product improve quality life patient increase access hiv medication consumer world follow agreement medicine people get treatment patent pool extend access dolutegravir need challenge include affordability country adult hiv fact disease open innovation develop world live treatment underresource health system share datum researcher address challenge tackle compound show sign activity read barrier affordability accessibility neglect tropical disease flexible pricing approach support research new treatment outside gsk reduce child mortality work key partner stimulate open innovation target area unmet medical partnership save need neglect tropical disease child reach million fight malaria people include million child mainly affect develop world european medicine agency adopt lifesave immunisation treatment noncommunicable disease cancer positive scientific opinion malaria intervention diabetes candidate vaccine mosquirix read recommend pilot rollout strengthen healthcare system country subsaharan africa world continue reinvestment profit generate launch new million partnership flexible pricing world poor country train comic relief fight malaria frontline health worker region cohi mye ita yee cri iee read strengthen health system un new global goal sustainable graduate gavi support read development sdgs health explicitly include maintain commitment cap goal number ensure healthy life price patent medicine strengthen healthcare infrastructure promote wellbee age vaccine develop country train additional frontline vaccine historic achievement support tackle big develop world price health worker welcome addition arsenal global health challenge newborn recently launch new medicine develop country reach preventive tool fight mortality malaria extend benefit usa price parity discount people million malaria commend glaxosmithkline medicine aim supercede product people regardless demonstrate resilience ingenuity live ability pay read develop valuable asset ray chamber secretarygeneral special envoy read health agenda malariagsk responsible business supplement health focus respond ebola zika humanitarian emergency response see critical public health emergency gsk commit work partner year million people displace unit begin outbreak ebola west africa help ensure proactive approach disaster emergency situation extend asia pacific region usa demand urgent response plan global health threat crise devastate family leave recently announce partnership save impact continue provide respond fast event similar access adequate food child national center humanitarian support affect region gsk crisis example work shelter healthcare disaster preparedness help community accelerate development candidate government biomedical advanced well plan protect care child gsk work partner humanitarian vaccine ebola unprecedented rate research development authority barda event disaster organisation prepare respond trial underway inception emergency situation instance collaboration critical fasttrack development lifesave able fast track development ebola vaccine contribute vaccine fact different donate cash product employee organisation include national institutes time invest longterm rebuild health usa wellcome reconstruction aftermath disaster trust government work gsk work save child common goal create strategic operational framework closely monitor outbreak humanitarian action mobilise zika virus brazil begin resource expertise organisation autumn reach strengthen response include partner collaborator brazil provide seed funding help save world assess situation feasibility child establish emergency health unit potential vaccine development team specialist health worker evaluate exist technology platform deliver basic healthcare hour believe potentially suitable disaster strike working zika virus vaccine experience particularly develop ebola vaccine useful anna pantelia event future outbreak recognise save child global community improve capacity prevent quickly control unpredictable disease outbreak help avoid devastating consequence human health economy global security aubrey wade donate support effort save child address global refugee crisisgsk responsible business supplement health innovation unmet medical need break open innovation approach tre canto researcher screen approach base principle access library million compound barrier effective compound datum great flexibility sign activity kinetoplastid healthcare open intellectual property partnership share group parasitic disease estimate infect expertise process infrastructure approximately million people develop innovation process world share hit identify disease develop world accelerate drug discovery researcher encourage research open innovation model continue advance field outside gsk area great unmet research disease develop world build similar exercise ddws malaria tuberculosis carry malaria medical need neglect tropical disease ntds scientific challenge dedicate research centre tre canto spain work exclusively develop new read innovative medicine disease eliminate control develop world support collaborate ntds organisation include wellcome trust bill melinda gates foundation noncommunicable disease ncds take unprecedented step open innovation model open facility external scientist accelerate research ncds africa ncds create world open lab visit include world big killer scientist work project africa ncd open lab appoint cancer diabetes heart disease chronic commitment adapt open innovation accessing gsk expertise resource independent external scientific advisory board respiratory disease like copd healthcare model currently disease capability year open chair lead african scientist research africa focus communicable develop world apply area open lab build portfolio research provide input strategy research disease ncds emerge great unmet medical need scientific project support visit scientist project select sub continent big killer recognise challenge include infectious disease result scientific publication saharan african country lab gap create africa ncd open alzheimer disease promise drug discovery lead additionally support researcher south african lab work partnership major project contribute generate institution partnership medical funder academic group government million follow grant enable research council south africa conduct ncd research africa effort researcher ddw research progress overview complete critical achieve world health assembly partner medical goal reduce avoidable mortality ncds research council university increase understand experimental medicine initiative explore new unique attribute ncds african patient therapie eminent open innovation research initiative aim support experimental medicine project inflammatory disease chronic obstructive pulmonary disease copd fibrosis approach ncds policy papergsk responsible business supplement health innovation unmet medical need continue research tuberculosis tackle antibiotic resistance research tuberculosis stalled increase resistance exist antibiotic alzheimer dementia year million people emerge urgent public health crisis dementia lead cause live poverty contract disease drug resistant infection responsible disability dependency old million die result death year problem people globally alzheimer disease time emergence spread multi exacerbate scientific economic prevalent cause dementia drugresistant present increase public obstacle discourage research develop extend open innovation model tackle health threat current treatment typically new antibiotic challenge focus publicprivate effective toxic costlier partnership new collaborative model despite challenge commit lead orchid alliance open collaborative advance research field found partner model tuberculosis lead optimization research unit focus develop million investment address urgent medical need fouryear generation antibiotic government dementia discovery fund multisector partnership cofunde active pipeline potential new medicine global fund dementia research european union complete aim development advanced asset fund design speed discovery develop new medicine drugresistant topoisomerase inhibitor gepotidacin development new treatment dementia available patient quickly gsk develop identify promote new avenue efficiently collaboration government research world biomedical advanced research development work alliance included repurpose continue participate authority barda asset novel betalactam compound potential anti accelerate medicine partnership mechanism action potential tubercular drug hit alzheimer dementia platform address multiple indication move compound collection identify target lead imis pharmacog project phase iii study follow positive january sign declaration future drug discovery programme create develop new tool test candidate phase result pharmaceutical diagnostic portfolio lead compound move drug treat alzheimer company commit work government hit precandidate selection stage collaboration barda parallel develop sustainable economic partnership involve advance phase clinical model antibiotic ensure sustainable government scientific institution trial candidate vaccine develop supply medicine future commitment end company accelerate development partnership aeras funding replace new new antibiotic key publicprivate bill melinda gates foundation commitment focus important collaboration field active global health challenge include member innovative medicine tackle antibiotic resistance initiative newdrugsbadbugs initiative disease develop world launch address key issue associate investment development new antibiotic government dementia discovery fundgsk responsible business supplement health well access medicine vaccine work affordability low middleincome supply gavi vaccine cervical middleincome country people country cancer cervarix pneumococcal disease live poverty flexible pricing medicine vaccine billion people live emerge market synflorix introduce approach enable people access available affordable million begin healthcare country commit freeze product halve price seretide time year flexible price develop country graduate inhaler device accuhaler evohaler people need pricing strategy seeks meet healthcare gavi support continue india increase sale volume matter live need provide product low price purchase vaccine significantly discount yearonyear extend access way price decade graduation philippine gsk introduce card afford global footprint broad product offering allow supply million lowcost dose synflorix coupon patient programme offering discount sell high volume product gavi dose mdecin san select product frontire immunise child catch crisis patient access cap price product include antibiotic augmentin patent medicine vaccine extend tiere pricing model zinnat seretide inhaler develop country ldc develop include prescription medicine develop programme world price long manufacturing cost pricing strategy base countryspecific cover tiere pricing circumstance patient affordability participate groundwork approach product country pay local healthcare system social dialogue multistakeholder platform alongside price base gross national income economic actor whilst increase national representative colombia ghana commitment embed flexible gni capita access product philippine thailand vietnam improve pricing strategy innovative business gsk pioneer tiere pricing model strategy know work evidencebase decisionmake health model prescription medicine improve access vaccine enable bangladesh example sale gsk brand system low middleincome country vaccine increase usage lowincome country roll national cefixime grow year result groundwork framework release able access afford product immunisation programme offer low reduce price help people outline plan government access oral antibiotic industry enable people obtain medicine price vaccine organisation gavi need price afford vaccine alliance support country gni head high level panel innovation access progress overview progressing supply nearly million dose issue report ceo andrew rotarix vaccine gavi enable ldc witty sit panel convene launch immunisation programme combat secretarygeneral ban kimoon rotavirus gastroenteritis common cause diarrhoea childhood mortalitygsk responsible business supplement health well access medicine vaccine continue affordability develop country build local capability capacity support community access healthcare affordability hinder access people build local capability improve access target product financial donation give develop country broaden access develop country provide patient help local global partner provide community product market consumer locally relevant product access healthcare global flexible approach retain return enhance domestic manufacturing community investment total million cash investment innovation example capacity capability compare million product usa recently launch new increase local access supply support include inkind medicine price parity discount important commitment africa time pulse medicine aim supercede cash donate million management continue evaluate option cash community worldwide include usa offer type patient manufacture nigeria total million health wellbeing assistance help ensure appropriate access invest academia africa education programme include medicine gsk programme collaborate royal society donate million strengthen healthcare eligible patient prescription chemistrys pan african chemistry network infrastructure ldcs primarily train drug coverage medicare university subsaharan africa community health worker prescription drug plan offer train scientist collaboration specialty product assistance eligible insure aim support development skilled product donation donate medicine patient result new coverage option workforce turn support vibrant value million support include available follow affordable care act local healthcare economy patient assistance programme patient insure fewer require million albendazole tablet fight announce plan establish patient assistance programme pap lymphatic filariasis soiltransmitte helminth new global headquarters asia commitment access product donation support singapore start work million continue provide service help patient humanitarian aid distribute pharmaceutical factory india operational understand alternative coverage option partner americare direct relief world factory manufacture billion tablet pap provide prescribed gsk health map international project hope billion capsule antiinflammatory medicine vaccine value gastroenterology medicine year expertise employee volunteer time patient indian market skill expertise worth million reach agreement brazil collaborate fiocruz government britain country develop vaccine tackle country nationwide vaccination programme health priority india joint venture meningitis potentially deadly infectious biological develop combination disease offer fair value national health vaccine disease viiv service ensure gsk continue healthcare sign innovative invest create new treatment vaccine manufacturing partnership desano pharmaceutical manufacturer provide hiv treatment dolutegravir competitive gsk value product donation cost good believe truer reflection cost gsk wholesale acquisition price china country cost pharma industry value product donation need great total value prescribe gsk medicine vaccine provide pap base wholesale acquisition cost gsk responsible business supplement health building product well meet need develop make medicine vaccine consumer develop new formulation format small pack size product product available appropriate format explore way exist affordable new formulation important strategy increase access product reformulate tackle different sell small sachet product format overcome healthcare well meet diverse need health challenge emerge market order patient healthcare system worldwide affordable example sensodyne accessibility barrier partnership save child toothpaste philippine horlick develop vaccine medicine investigate use skin emollient extend reach need keep cold contain sunflower seed oil reduce nutritional supplement india singleunit inhaler product ventolin rotacap lifesave product vaccine need keep cool risk infection dehydration hypothermia rotahaler device help patient live storage distribution cause severe acute malnutrition asthma copd manage cost remain effective develop country child submit regulatory treatment buying little time enable maintain cold chain right application european medicine agency patient particularly receive wage patient challenge antiseptic gel prevent umbilical cord daily weekly basis access critical infection newborn reformulate partnership bill melinda medication ventolin rotacap rotahaler chlorhexidine solution gate foundation reformulate critical device register country corsodyl mouthwash liquid component rtss candidate expand reach patient philippine work reduce child mortality malaria vaccine enable remain stable indonesia vietnam nigeria kenya year temperature combine vaccine treatment commitment continue build core june demonstrate stability extend coverage reduce number range product format well year month dose need transport meet need people globe aim integrate thermostable administer health worker simplify include able access formulation global malaria strategy complex drug regimen patient afford product easy transport store vaccine flu vaccine protect people hot region like subsaharan africa strain influenza single people risk disease dose bangladesh begin clinical study progress overview progress medicine need refrigerate test fourdose vial synflorix oxytocin manufacture hormone pneumococcal vaccine supply gavi reduce excessive bleed birth successful new format reduce single big cause maternal mortality storage space cold chain capacity liquid oxytocin hard access develop require transport use vaccine country lack proper refrigeration viiv healthcare investigate train healthcare worker administer combination multiple drug provide injection collaborate monash treatment option simplify complex university australia partner drug regimen people live hiv viiv develop heatstable lowcost inhale form healthcare dedicate paediatric group oxytocin begin clinical trial focus develop antiretroviral treatment new dry powder formulation adapt infant child gsk responsible business supplement health reduce child mortality vaccine approximately children insight ontheground knowledge pulse volunteering programme die day preventable cause save child work gsk employee medicine pioneer social economic inequality reformulate antiseptic chlorhexidine solution volunteer save child partnership save underfive mortality lowincome country gsk corsodyl mouthwash gel encourage employee fundraising time high highincome country prevent umbilical cord infection issue child partnership begin gsk employee exacerbate develop country commit help save million raise million contribute urgent birth place home proper children live world poor country increase million match health care october submit effort reduce child groundbreake partnership regulatory application european medicine funding gsk money raise save child effort include develop support health programme kenya agency approve use offer mortality globally childfriendly medicine widen immunisation drc save childrens antiseptic gel notforprofit price coverage accelerate access treatment humanitarian relief effort local programme share knowledge strengthen healthcare system country world manufacture locally read work commitment important contribution save child page effort reduce child mortality global goal sustainable development vaccine immunise child critical end preventable death newborn programme save child reduce childhood mortality child year age democratic republic congo drc kenya work gavi provide reducedprice aim establish model replicate partner help save million vaccine help protect million develop country example children live child disease rotavirus drc child year partnership save pneumococcal disease commitment continue invest innovative die reach fifth birthday child combine capability crosssector partnership reduce child deliver essential service neonatal commit donate supply chain procurement vaccine mortality maternal child health kenya million tablet albendazole year charitys expertise work support charitys newborn child survival support goal deworm vulnerable child deliver programme train community child country intestinal tangible result date reach health worker set community health unit worm endemic progress overview track million child underfive refurbish maternity centre fully immunise child health worker training programme treat diarrhoea malaria february announce winner focus reduce child pneumonia million child annual million healthcare innovation maternal mortality rural community screen malnutrition award set gsk save child example nepal work care reward sustainable scalable healthcare international government improve innovation result tangible maternal neonatal reproductive health improvement underfive child survival improve skill frontline health rate winner include innovation worker provide health equipment strengthen health system community enable local community feedback programme treatment strategy health centre perform quality africa asia south america overall services provide support winner digital immunisation system health worker nepal train develop path south vietnam reach million beneficiariesgsk responsible business supplement health strengthen healthcare infrastructure reinvestment world face estimate shortfall amref health africa support elearne child mozambique nearly million frontline health worker lack training nurse midwive register mvaccination pilot develop country ldc train health worker present tanzania uganda programme vodafone seeks improve train fundamental barrier access quality healthcare vaccination rate mobile phone parent gsk support million community people world poor country caregiver receive update phone frontline health worker health worker campaign advocate remind vaccination partner training frontline health recruitment formal recognition ministry support million worker support community education health million community health worker vaccination visit record underserved people advocate increase investment health funding pilot train health worker addition healthcare worker responsible system strengthen ghana campaign aim showcase recording vaccination stock level catalyse investment programme refrigerator temperature weekly basis reinveste healthcare phone average stock ldc operate reinv increase access healthcare update cold chain update week profit sale pharmaceutical deliver longterm economic growth africa record facility december consumer healthcare product train expand health worker training service expand facility educate community frontline health worker ldc ghana kenya nigeria country reinveste support amref health africa train health funding usaid gavi randomize million ldc profit country worker kenya manage diabete control trial measure impact pilot training frontline health worker childhood asthma work assess cost effectiveness inform decision commitment continue work partner include midwife nurse community save child build capacity scale programme mozambique support strengthen healthcare health worker volunteer frontline health worker nigerian african country infrastructure anticipate improve turn reach million people state reach child contribute joint initiative access healthcare million underserve mother end ensure sustainability reinvestment international telecommunication union people aim train health worker programme tailor meet specific assist government use mobile technology benefit million underserved patient community need align government health prevent treat noncommunicable disease prioritie work partner amref health partnering develop new healthcare develop develop country progress overview progress africa care international save child delivery model initiative target risk factor condition focus training frontline health worker explore technology new smoking hypertension diabete poor diet educate community basic preventative business model transform costa rica example campaign health build capacity improve health way healthcare deliver develop text message help people stop smoke facility equip training centre advocate country world encourage participant quit improved policy increase investment gsk threeyear partnership barclay begin work marie stope government support seeks develop new business model international ngo pilot scalable care international train midwife increase access healthcare stimulate women health intervention programme local community bangladesh economic development zambia bangladesh madagascar sierra leone formally accredit salaried government work launch oneyear pilot screen prevent treat cervical cancer social enterprise care international programme target woman aged save child successfully lobby mali train community entrepreneur sell health expand roll government recruit health professional product doortodoor cervarix cervical cancer vaccine young girl demonstrate effectiveness community health worker training programmegsk responsible business supplement health eliminate control neglect tropical disease partner ntds group communicable disease albendazole donation research new treatment prevalent develop country pledge donate albendazole long scale complexity ntds require free million affect billion people nearly need help eliminate mosquitoborne open flexible approach innovation people debilitate people worldwide suffer worm disease cause disfigure swell addition group dedicate ntd debilitate effect include limb genital know elephantiasis ntds disease develop effect neglect tropical disability disfiguration death commit provide million world ddws prioritise research disease ntds detrimental impact health albendazole tablet year help treat school area tre canto open lab economy world poor country age child risk intestinal worm gsk found member wipo soiltransmitte helminth endemic research open innovation platform partner london seek accelerate development new declaration ntds commit donate million albendazole well treatment ntds control eliminate tablet elimination million tablet ntds partnership major treat intestinal worm total donate open innovation process result pharmaceutical company organisation nearly billion tablet year reach publication highquality hit academic ngos national government million people include million ntds screen million release annual report scorecard school aged child compound collection scientist progress work tre canto progress commitment help eliminate control target challenge remain contribution develop preclinical candidate ntds affect billion people focus largescale donation albendazole treat visceral leishmaniasis promising include elimination lymphatic filariasis efficient forecasting manufacturing shipping precandidate drug combat chaga disease continue investment donate product global research advocacy ongoing product donation contribution london declaration ntds donation albendazole enable deworme school age child endemic country extensive effort ntds focus african sleeping sickness progress overview progress chaga disease leishmaniasis effort hope significant contribution new target end ntds form global goal sustainable development albendazole tablet donation total tablet elimination tablet treat intestinal worm total gsk responsible business supplement health fighting malaria year research child africa die malaria open innovation approach partnership fight malaria minute age malaria addition significant investment support africa close poverty closely link community development vaccine prevent malaria malaria partnership promote use exist making available high risk disease continue research new intervention bed net indoor residual access prevention diagnosis well treatment contract spray antimalarial treatment world vaccine treatment disease research result continue partnership devastating disease discovery preclinical candidate year partner amref health africa save child effective current malarial parasite work develop vaccine train health professional community health protect young child deadly parasite stimulate external drug discovery research worker tanzania kenya respectively reach significant milestone malaria publish promising continue work fhi journey european medicine agency hit compound collection carter center combine intervention adopt positive scientific opinion control malaria ntds ghana nigeria work mmv malaria candidate vaccine mosquirix rtss faiths act sierra leone train progress development tafenoquine child age week month faith leader malaria ambassador drug treat prevent vivax malaria recommend rtss strain occur primarily south south december launch new introduce pilot rollout east asia latin america horn africa partnership comic relief charity actively work financing body phase iii trial programme currently fight malaria strengthen health system commitment build year malaria vaccine clinical trial partnership investigate tafenoquine adult patient million partnership create commitment contribute fight include path gsk generate support vivax malaria million donation gsk million malaria continue pilot finalise design comic relief grant frontline investment partnership ground pilot implementation programme organisation malaria endemic country complement intervention global gsk develop rtss partnership health funder grassroots organisation path malaria vaccine initiative funding collaboration aim support progress overview progress bill melinda gates foundation target reduce malaria case vaccine candidate target malarial parasite death support falciparum prevalent sub global goal sustainable development saharan africa trial show use bed net insecticide help protect region vulnerable child gsk commit supply rtss notforprofit price price cover cost manufacturing vaccine small return cent reinveste research developmentgsk responsible business supplement health eradicating polio vaccine polio infectious viral disease mainly affect child know cure technology support instance cause lifelong paralysis eradication polio past year world poliofree gsk play key role achieve partnership organisation commit support goal completely eradicate disease september announce polio long endemic nigeria follow milestone india declare poliofree good news virus remain endemic country commitment continue support afghanistan pakistan eradication objective eradicate polio global threat polio remain new provide vaccine unicef outbreak confirm madagascar achieve global polio eradication initiative gpei supply oral polio vaccine opv country need progress overview progressing deliver million dose opv inactivated polio vaccine ipv replace contribute opv country disease billion dose expect meet eradicate prevent reemergence threeyear contractual commitment gpei disease supply ipv develop deliver million dose country invest new ipv facility supply million million belgium begin production dose oral polio vaccine scientist recommend form qualivax joint venture transition opv target disease indian pharmaceutical company biological strain instead usual remove create combination vaccine include type strain detect inactivated polio virus ipv vaccine small risk disease disease single dose expect reemerge vaccine eliminate vaccine available follow line strategy ready eradication polio combination vaccine successful switch twostrain vaccine important tool help prevent april stockpile large resurgence disease particularly amount opv keep available use develop world unicef event outbreakgsk responsible business supplement health access antiretroviral treatment hiv research worldwide million people live hiv increase access hiv treatment care improve outcome key affected adult child getting extend access hiv treatment care population collaboration treatment support effort work priority particularly lowincome country stigma remain big barrier develop increase universal coverage priority nearly people affect hiv live people getting test disclose hiv status develop new medicine hivaid ensure viiv healthcare access programme reach start treatment access treatment access people need country worldwide royaltyfree voluntary support hiv community fight stigma hivaid licence enable generic manufacturer sell discrimination promote healthcare access product donor agency public sector working community base deliver new treatment programme significantly reduce price organisation stakeholder tivicay dolutegravir approve fda available country follow agreement medicine target effort key affect population triumeq combine antiretroviral drug patent pool mpp unbacked organisation reach great risk hiv infection approve available encourage voluntary licencing patent programme include million positive pooling viiv healthcare introduce action child fund support prevention innovative formulation delivery method mpp licence tiere royalty system mothertochild transmission raise vital people live hiv viiv healthcare tailor national gdps strategy extend awareness hiv prevention testing care working janssen pharmaceutical research access dolutegravir country adolescent girl woman man commitment viiv healthcare company develop twodrug single tablet adult hiv develop world live sex man transgender community continue research new treatment regiman combine dolutegravir rilpivirine paediatric formulation drug example announce million increase access medicine care patient virally suppress country child million fouryear accelerate initiative people live hiv world explore combine cabotegravir hiv live catalyse community support black gay support unaid deliver rilpivirine longacting formulation bisexual man city hard hit hiv ambition administer frequently help improve access work community combat stigma exist medicine make easy facilitate approval process generic antiretroviral treatment coverage low discrimination associate hiv people adhere treatment addition version dolutegravir partnership child adult viiv healthcare investigate use cabotegravir clinton health access initiative enable dedicated work stream develop prevention highrisk population indian pharmaceutical company aurobindo file formulation therapy well suit infant application fda generic child age develop ongoing research antiretroviral progress overview progress approval dolutegravir fda approval paediatric tastemasked formulation abacavir treatment support clinical generic dolutegravir supply lamivudine improve adherence child study involve patient president emergency plan aid relief therapy receive tentative approval africa asia studies address licensed country outside usa fda treatment partner area patient region include europe tivicay triumeq mylan clinton health access initiative prevention mothertochild transmission available patient relevant working available coinfection paediatric adolescent national health service country cover license agreement finding study inform local global hiv treatment programme viiv healthcare website improve access patient region information include new series policy people live hiv know hiv status document key issue diagnose receive sustain antiretroviral therapy receive therapy undetectable viral loadgsk responsible business supplement behaviour january long pay hcp speak prescriber medicine vaccinesgsk responsible business supplement behaviour approach drive value highlight develop testing manufacturing work party new medicine engage government introduce comprehensive new appropriate policy programme strengthen management environmental social risk rigorous standard control transparency clinical trial datum supply chain identify prioritise patient safety transparency act high risk supplier distributor integrity research clinical trial give research team access undergo assessment continuously monitor report clinical trial datum enable programme potential adverse effect medicine research maximising contribution vaccine prescribe physician thousand volunteer patient participate study patient expect employee supplier sale force put patient live value mandatory annual training need ensure people know code conduct january complete rollout read measure performance change way sale team deliver deliver read compensate globally pharmaceutical line value medical representative long increase transparency significantly change commercial individual sale target gsk rank model lead industry way sell ethical conduct transparent ftse market medicine ensure patient people complete mandatory read company transparency international needs come pharmaceutical medical annual training code conduct corporate political engagement index representative world long include complementary worker think interaction individual sale target instead require training pharmaceutical industry doctor open assess compensate base time critique interaction industry knowledge quality service deliver health professional community healthcare professional hcp need open transparent broad business performance read core value respect people sir michael rawlin human right fundamental gsk chair medicine healthcare signatory global compact read product regulatory agency explore implement guiding principle business human right value chaingsk responsible business supplement behaviour focus ethic compliance academy value dictate behave guide nick hiron head global ethic decision global ethic compliance say wanted compliance team play major role embed training people development valuesbase culture provide tool journey compliance professional ethic establish robust internal control create compliance expert goal help ethical culture people feel comfortable participant help business value raise concern base decision recognise confidently navigate ethical grey zone introduce new ethic compliance academy provide indepth academy building network train external certification member inform engage effective ethic team worldwide aim innovative compliance officer run academy model strengthen compliance ethic session employee country promote common approach ethic agree learn new skill compliance business agree academy valuable use time day interactive activity case study presentation internal plan develop specialise version external expert participant learn academy senior leader employee apply gsk value practically day day legal human resource audit function basis detect potential risk area enhance knowledge ethic business completion compliance create strong course participant successfully pass ethical culture gsk examination receive lead professional ethic compliance lpec certification issue ethic compliance initiative eci nonprofit organisation complete course achieve pass rate average score run academy session employee countriesgsk responsible business supplement behaviour ethical conduct guide training employee expectation embed value performance train people value measurement value integrity practice right choice live value expectation transparency focus face ethical dilemma code use measure employee performance conduct dedicated online resource centre global performance system patient respect provide guidance tool need put emphasis way employee people apply value everyday activity achieve result result work world continue focus embed value performance employee complete management extend exist mandatory annual training code recoupment programme cover approximately conduct online course available senior manager globally language include training fundamentally change compensation model value ethical leadership antibribery sale team focus patient need corruption reporting issue promote value concern sale marketing practice increase manager accountability antibribery corruption ensure employee commitment continue strengthen training extend mandatory zero tolerance bribery corruption valuesbase culture training training complementary worker form antibribery corruption people standard expect time employee fail complete abac programme include risk assessment encourage reporting concern course face disciplinary action standard additional training people embed value way define permit local labour law work high risk area measure employee performance people receive write verbal employee complete training roll new simple warning fail complete course framework engage train party require time frame base risk profile grant extension progress overview progress employee survey respondent agree work environment encourage ethical behaviour face pressure meet business objectivesgsk responsible business supplement behaviour ethical conduct continue reporting investigate misconduct disciplinary action centrally track misconduct allegation disciplinary action take employee employee discipline concern security incident receive fail act line policy breakdown type policy violation speak channel monitor employee discipline policy violation route receive type policy violation report allegation majority chart remain broadly attendancepayroll attendance payroll remain ood manufacturing practice good distribution practice speak channel offer people big type violation total ravel expense outside gsk opportunity ask follow good manufacturing marketing promotional activity question voice concern anonymously practice travel confidentially independent expense violation increase code conduct party phone online increase frequency monitor local work regulation unauthorised absenteeism concern raise review total discipline receive verbal ehssafety formal investigation initiate warning employee receive falsification document response allegation document warning training completion frequent category allegation dismiss agree leave employee performancerelation product company voluntarily high number promotion interaction hcp fraud dismissal relate travel expense abac policy violation account dismissal follow dismissal relate code conduct violation attendancepayroll violation like pharmaceutical company face complex product liability antitrust patent litigation investigation operation conduct governmental regulatory agency detail ongoing investigation set annual reportgsk responsible business supplement behaviour promote value sale marketing practice transform create sale force put patient change way engage hcp disclose payment hcp need remain committed ongoing dialogue gsk commit disclosing payment way compensate january complete rollout scientific community support hcp healthcare organisation salesforce engage change way sale team medical education make change individual aggregate basis compensate globally pharmaceutical transform modernise way engage country include australia healthcare professional medical representative world hcp january long denmark france japan netherlands ensure patient need long individual sale target instead pay hcp speak prescriber portugal slovakia line incentivise base technical prescription medicine vaccine locally agree government industry come knowledge quality service deliver continue pay hcp provide service association code plan disclose healthcare professional hcps support participate clinical research payment aggregate basis canada improve patient care broader set payment govern rigorous control support increase transparency business performance measure sale base fair market value country industry association team listen customer need gsk change way support medical government establish specific guideline right gsk resource help support education long play role choose disclosure example new code delivery improve patient care healthcare professional sponsor disclosure payment hcp usa approach generate strong attend scientific congress instead european federation pharmaceutical positive customer feedback survey company provide fund independent industry association efpia require commitment continue drive value hcps july gsk rank professional body allocate funding payment january base approach sale marketing trust customer value second time individual industry onwards report annual basis practice world interest row simplifying system resulted support independent medical education report expect publish consumer patient core significant increase engagement level provide grant funding recognise education june sale team employee survey provider programme independent respondent agree pharma influence programme content make change necessary compete provide information medicine progress overview progressing say proud work gsk vaccine way hcp want sale marketing employee want make significant investment relevant party follow code digital platform capability practice promotion customer interaction inhouse medical capability market gsk expert speak hcp find highly effective informative canada stop payment hcp early gsk expert speaker deliver number medical product information session june external hcp attendee comment strong scientific knowledge communication skill gsk speakersgsk responsible business supplement behaviour transparency clinical trial datum advance medical safety effectiveness new medicine pharmaceutical company initially proposal review panel demonstrate clinical trial sign alltrial campaign trial external independent expert appoint science patient care provide great access datum register result report gsk wellcome trust take provide great access trial regardless result campaign receive support investor management panel appoint new consider positive negative allow represent trillion asset member important step clinical trial information conduct research usa europe australia achieve vision independent datum help ensure maximise contribution sharing system include study committed share detailed thousand volunteer industry academia discussion patientlevel datum sit clinical trial patient participate study group drive progress result support research harvard multiregional clinical trial centre online clinical study advance science improve patient care wellcome trust arnold foundation register available information datum anonymise protect patient national academy medicine trial include summary result confidentiality access researcher submit research proposal independent past number year lead review panel ensure datum industry share information datum commitment transparent possible valid scientific enquiry trial advance medical science patient clinical trial datum include publishing care company clinical clinical study report patientlevel study report csrs publicly available datum outcome trial medicine formal report basis submission conduct gsk appropriate regulatory agency include detailed process make available researcher research proposal information design method result access anonymise patient level datum submit access trial post clinical study scientific enquiry gsk trial datum register patient personal information remove register include year system set gsk summary trial result csrs researcher request access datum progress overview complete wwwclinicalstudydatarequestcom list global clinical trial conduct formation gsk include clinical trial company end research proposal submit access datum gsk trial give research team access detailed trial datagsk responsible business supplement behaviour rigorous patient consumer safety patient safety paramount understand risk global risk register help research combat risk counterfeit product prescribe take medicine team track risk quality safety company immune threat development health worker patient need know standard risk identify counterfeit product impossible testing manufacturing associate risk benefit regular audits trial eliminate risk completely commit extensive control place design conduct party minimise patient consumer receive product detect evaluate communicate benefit behalf perform audits authentic medicine healthcare product risk potential safety concern datum summary collaborate multiple stakeholder product effectively tackle public health threat ensure quality manufacture supply support global fight fake research team assess benefitrisk produce million dose campaign aim raise awareness profile medicine development vaccine billion pack medicine danger counterfeit medicine use result review billion pack consumer global safety board make decision healthcare product manufacturing case report product safety issue chair chief site world confirm counterfeit gsk product medical officer compose senior country raid action conduct committed meeting high commitment continue ensure physician scientist board oversee target involve manufacture standard stringent quality control interest safety patient consumer policy control product safety good distribution andor sale counterfeit gsk quality assurance process medicine paramount importance way practice share business product result arrest vaccine manufacture accord design undertake clinical trial internal risk advisory panel good manufacturing practice cgmp continue support interpol product quality assurance monitoring collaborate industry peer regulator regulation internal quality management pharmaceutical company report adverse event ongoing healthcare provider enhance detection system regulatory threeyear industry initiative combat product usage monitor understand prevention inspection pharmaceutical supply site counterfeit brand generic adverse effect know pharmacovigilance vast majority conclude satisfactory drug initiative target organise crime gsk award bioit world outcome working regulator involvement manufacture distribution good practice award collaboration bring inspection remain concern sale counterfeit pharmaceutical progress overview progress informatic company epidemico monitor publicly acceptable conclusion vaccine raise public awareness danger available information social medium gain business regulatory inspection purchase counterfeit drug particularly insight adverse effect medicine consumer healthcare supply site purchase online satisfactory outcome put patient safety clinical research extend supply chain serialisation trial conduct accordance internal control supplier programme fingerprint package international conference harmonisation requirement design ensure line manufacture site good clinical practice guideline consistent high quality safety programme apply unique serial fingerprint employee involve trial train production product endtoend product log good clinical practice trial start approach safeguard patient consumer governmentmanage database product independent ethic committee review safety help deliver high quality verify point supply chain protocols committee prevent trial product improve safety performance conduct reduce wastegsk responsible business supplement behaviour minimise animal testing work new medicine vaccine undergo careful develop alternative animal study check assess effect human reduce need vivo change animal use index year alternative animal body animal study provide vital information live body animal study researcher need research ensure obtain alternative method nonanimal testing method model form legally require test medicine function live human tissue animal vaccine animal start clinical sponsor development computer require trial protect patient unexpected model predict drug concentration human potentially lifethreatene adverse effect base vitro outside body datum require use animal release sponsor collaboration use vaccine amoeba replace rodent certain study apply establish approach partner university college london replace animal research possible explore human cell tissue reduce number animal need refine technique improve animal welfare scientific enable vitro testing potential animal gsk facility replacement animal study animal contractor behalf gsk peer review challenge need animal ongoing experimental project european study integrate nonanimal animal figure normalise year datum commitment rigorously challenge need bioinformatics institute sanger centre formation gsk testing approach ensure study animal study work minimise area gsk scientist lead variation method collection collation relevant reproducible animal number gsk novartis animal impact animal welfare invest crosspharmaceutical group partner number novartis site include development alternative study share few animal national institute health usa design animal number figure report cycle resolve reporting cycle animalbase datum continuation downward trend test artificial organ system call organ year tie change project chip drug safety testing program commitment ensure animal welfare sponsor project national animal rodent office animal welfare ethic centre replacement refinement progress overview progress strategy lead chief veterinary medicine reduction animal research ncrs oversee humane responsible use create vitro system replicate ability animal team train motivated human skin ability metabolise substance prioritise animal welfare recognise explore nonanimal method assess innovative idea animal welfare award safety new gene therapy treatment standard process ensure animal increasingly use vitro method welfare apply animal study conduct quality control vaccine big gsk contractor supplier requirements animal testing sector work contractor fail support european commission implement recommendation partnership accelerate acceptance commitment improve alternative animal use regulatory testing animal programme care welfare treatment animal gsk novartis vaccine consumer healthcare currently integratedgsk responsible business supplement behaviour promote human right working address gsk signatory global compact human right steering group provide activity embargo country set key principle business companywide direction oversight help operate country target sanction human right impact human right commit uphold ensure meet commitment human law cuba iran north korea commitment universal declaration human right right set human right statement sudan syria raise concern core labour standard set steering group focus managing stakeholder represent challenge support guiding international labour organization thirdparty risk particular emphasis risk business sanction principle business public policy statement work lift iran remain force guiding principle business party labour right health safety comply disclosure requirement human right human right set clear expectation steering group address gsk position iran threat reduction syria human business respect human right undertake living wage ensure children right right act independent thirdparty assessment integral consideration human help understand potential human right believe people access right broadly transparency impact associate business essential medicine regardless countrys requirement modern slavery act identify seven priority area access health regime people need medicine care air quality impact relate propellant gsk living wage accredit employer vaccine aim supply include clinical trial standard employment practice pay essential medicine sanction country patient safety product counterfeiting use employee live wage compliance applicable sanction thirdparty supplier accreditation extend commitment export control appropriate work commitment address guide effort area outline thirdparty contract employee partnership gsk medicine principle business human relevant section report vaccine available particular right operation particular focus improve alternative exist supply supranational supplier relationship companywide risk management control group like unicef direct government use thirdparty supplier privacy datum security identify key risk area introduce employee supplier ensure comprehensive new programme strengthen personal datum collect process progress overview track management risk find transfer store appropriately securely programme line global privacy principle legal requirement website summary bind corporate rule safeguard personally identifiable informationgsk responsible business supplement behaviour ensure ethical interaction commit political advocacy gsk corporate political european health advisory board hab bring interact regularly government contribution sponsor political patient group leader gsk engage ethically policymaker stakeholder advocate meeting world insight key policy initiative issue transparently political policy encourage innovation promote employee financially support political group reflect good interest patient efficient management healthcare spend individual candidate political action hab discuss patient involvement research key stakeholder patient support need committee pac federal election change make work campaign act gsk employee healthcare professional employee involved lobbying activity pac contribute state federal follow relevant requirement set patient advocacy leader summit candidate fund contribute code conduct expect pal bring diverse group federal candidate fund thirdparty policy group engage patient advocacy leader gsk employee contribute candidate state office behalf share value build understanding develop skill comprehensive criterion guide selection find gsk public policy identify way collaborate appropriately group standard operating position political advocacy pal event hold germany procedure manage public policy group japan slovenia switzerland usa engage patient advocacy group commitment demonstrate gsk reflect criterion train relevant focus critical role patient advocacy engage support patient interaction patient advocacy group employee related global policy organisation gain insight enable gsk found member patient political stakeholder conduct grant donation develop product advocate policy focus medicine development initiative appropriately ethically transparently gsk rank well meet patient need bring stakeholder transparent ftse company include patient organisation research new global standard interaction transparency international corporate development work comprehensive patient organisation outline work political engagement index index assess systematic approach patient involvement progress overview progress patient group collaborate project open company political clinical development gather insight ethically transparently engagement quality reporting funding gsk exceed political activity govern patient group annual revenue manage implement respect independence seek register lobbying cost transparency endorsement promote medicine register federal lobbying register publish information financial cost represent interest nonfinancial support provide institution range patient organisation website federal lobbying activity activity include run advocacy office brussels washington cost consulting travel include run advocacy office brussels salarie trade association membership fee representation consulting cost activity increase year year declare figure higher publish new rule guideline publicly list membership trade transparency register gsk follow european trade association efpia interpretation guidance implement newly industry association lobby indirectly revise guideline behalf website list federal lobbying register figure cover cost salary benefit employee register lobby government lobbying consultant cost research run government affair office washington support staff include proportion gsk trade association fee associate federal lobbying reporting error spend federal lobbying activity incorrectly state responsible business supplement correct figure state heregsk responsible business supplement behaviour approach tax understand responsibility pay relationship tax authority figure give country appropriate tax fully support seek maintain open positive relationship give year view isolation accurately corporation tax effort ensure company appropriately government tax authority worldwide represent picture amount report year pay transparent tax affair manage welcome constructive debate taxation core financial result billion corporation tax globally policy appropriate mean group representative gsk tax position time pay billion substantial business employment enter arrangement nearly global total presence country world transfer price continuous audit programme advance net sale global net sale pay significant tax include line current oecd guideline base pricing agreement agreement provide corporation business taxis transfer pricing policy arm length group pay corporate longterm certainty tax authority tax associate employee principle support transfer price income tax gsk tax treatment gsk business time responsibility economic analysis report worldwide profit shareholder financially efficient international tax framework nature operation mean represent cash tax rate deliver sustainable tax rate support oecd principle intellectual property manufacturing correspond tax pay supply chain operation centre number key accounting tax charge profit approach look align commensurate profit make location consequence investment strategy country activity take place base erosion crossborder supply route necessary substantial economic activity taxis profit shift bep project constructive ensure supply medicine numerous government policy promote tax corporation tax pay modernisation principle addressing end market complex regime attractive business additional business taxis anomaly grow time investment patent box tax haven tax collect believe multinational economic engage artificial tax arrangement employee income tax pay considerable tax activity country world business commercial significant proportion global basic principle mean profit substance substantial local business corporate function manufacturing arise tax different location presence vast majority territory activity locate include country country report operate business corporation tax profit generate support implementation oecds office sale force manufacture facility indirect tax employment taxis recommendation countrybycountry local distribution product precise amount fluctuate year year corporation tax pay reporting cbcr key success contribute economic development create year governance bep project align core value share value region business robust internal policy process transparency integrity support training compliance programme ensure exchange cbcr datum tax authority alignment business datum validate exist information meet tax obligation audit risk hold taxpayer support ability committee board responsible ensure multinational group pay right approve tax policy risk management tax tax payment vary year year investment return generate long term investment cyclegsk responsible business supplement behaviour work party aim build strong supplier party include large supplier base need focus expect supplier party agent distributor affiliate company effort work high comply gsk quality safety standard relationship equity stake help develop risk noncompliance standard global manufacturing supply team continue party support distribute medicine vaccine product responsible business follow review manage regularly assess performance patient consumer need supplier identify supplier support manufacturing business share consider highrisk base country specifically quality ethical environmental year spend billion pound tens value operate type product service health safety ehs management system thousand supplier wide range good provide value contract assess supplier service essential strengthen identify highrisk distributor line quality management system relationship supplier party conduct assessment focus key audit supplier specifically eh critical business work risk antibribery corruption labour right share value operate responsible completion audits identify area promotional activity information protection ethical manner support commitment improvement work supplier develop increase use preferred supplier identify highrisk improvement plan check plan supplier undergo assessment form implement agree time frame extensive questionnaire environment significant concern identify suspend collaborate supplier manage labour human right fair business practice terminate work exist supplier commitment seek work environmental impact create product sustainable procurement manage decide work potential new supplier party share commitment high medicine example supplier risk supply chain response ethical standard operate responsible innovation forum support supplier assess external expert way performance gap identify manage thirdparty risk supplier provide support evidence responsibility support supplier appropriate commit working addition meeting gsk antibribery demonstrate appropriate policy pay time place party improve performance corruption labour right standard management system place exception standard payment term small medium sized company relevant expect party base risk assessment small diverse supplier usa comply standard quality safety questionnaire score additional diligence number initiative underway health safety environment progress overview track require include detailed review continuously improve experience principle clearly set contract clause monitor activity supplier work public statement work party high risk supplier onsite audits introduce comprehensive new commitment diversity time strengthen management programme strengthen management inclusion support supplier run group risk exist supplier risk supply chain focus underrepresented supply chain global deployment programme programme ensure party own woman minority ensure country capability risk assess gsk principle disabled veteran supplier diversity process place assess thirdparty risk contract amend necessary programme engage mentor small new supplier end diverse business supply chain help identify potential area growth usa procurement spend small business gsk responsible business supplement people pulse volunteer partnership employee use professional skill create sustainable change nonprofit partner community servegsk responsible business supplement people approach invest people ensure longterm highlight sustainability business order help engagement inclusion tackle big global health challenge employee sign government need talented motivate resilient workforce workforce take global disability confident campaign employee survey commitment remove barrier employment aim create work environment employee feel value respected opportunity disabled people empower inspire listening read support people particularly important year significant change business disabled people find read progressive approach lock employment employee health go conventional initiative disability confident health safety remain fundamental healthy workforce employer like gsk set bar focus energy resilience important people take provide unprecedented access preventive global energy resilience mark atkinson health service programme ceo scope help employee learn new skill talent development gain new experience support personal recruit apprentice read ambition drive business forward graduate postgraduate volunteer combine development opportunity employee country volunteer example pulse read provide preventive healthcare provide million worth skilled programme benefit people business addition healthcare benefit service nonprofit partner nonprofit partner establish market global partnership pulse volunteer programme prevention programme provide early talent community gift diverse represent future dynamic preventive healthcare read employee family member organisation business benefit diverse workforce clear fresh idea varied experience promote well decision make develop leader reflect understand market serve develop local talent mentor aspire female leader read disability confidentgsk responsible business supplement people focus inspire generation scientist need million aim build experience new scientist engineer solve future create global stem education challenge include big health programme employee tool challenge tomorrow researchle need inspire foster healthcare company gsk play lead generation scientist engineer worldwide role inspire young people science gsk offer range career opportunity technology engineering math stem stem area range summer internship provide range career opportunity apprenticeship graduate postgraduate science education early talent team programme apprenticeship programme stem ambassador offer school college leaver opportunity engage young people demonstrate realworld join company variety role science engineering school manage finance laboratory science graduate apprenticeship programme engineering apprentice learn onthejob value member team rhiannon lowe head team progress work nationally recognise ambassador volunteer gsk employee qualification ultimately transition site ware hertfordshire permanent role programme begin alongside job investigator investigative safety scheme grow steadily drug metabolism focus ambition continually expand disease develop world gene therapy programme new geography help nurture new generation talent team expertise practice add diversity business inspire people age school demonstrate scientific experiment host visit gsk lab student give opportunity involve science connect directly work real world rhiannon encourage girls particular pursue subject young age woman represent stem job young tell teacher study drama enjoy science math end complete phd virology immunology parttime whilst gsk say stem ambassador ukgsk responsible business supplement people develop people inspire healthy workplace attract retain need motivated talented people performance right skill knowledge help tackle global performance system listen employee good people foster world important health challenge employee set objective support employee resilient healthy people strategy focus area development business strategy share view employee survey talent leadership performance engagement underpin set clear expectation response rate workforce create emphasise result people achieve provide valuable feedback talent inspire place work way achieve line value number graduate postgraduate result survey tell employee join programme increase engagement clear accountability feel recruit graduate postgraduate help people understand empower perform role future leader esprit programme contribute success business right way globally exceed target provide regular update mission encourage mark welcome apprentice strategy progress live broadcast improvement manager support woman number discipline message ceo member worklife balance communicate location look expand corporate executive team listen reason important change apprenticeship programme people critical success external benchmark geography people record workforce commitment continue create working take employee survey provide result show engagement environment inspire people grow leadership valuable feedback help well score whilst remain positive fallen perform healthy resilient way provide employee level skill employer box thank staff sharing give significant change need advance career view donate save child gsk unexpected particular emphasis leadership development person complete survey support succession planning business put place strategy progress overview progress line leader complete welcome novartis employee improve engagement track leadership programme help transition gsk clear regular communication critical progress range measure managerial role train whilst onboarde new colleague include active use interim people globally act coach value expectation performance system survey help fulfil leadership potential local employee practice programme major reshape global pharmaceutical launch enterprise talent business occurring time place initiative strengthen leadership pipeline equal focus support employee leave initiative accelerate development company outplacement service provide leader potential aspiration effective coaching assistance consult executive role employee representative include year participant sponsor union work council change business leadership team attend business affect event design develop enterprise external perspectivesgsk responsible business supplement people develop people inspire healthy workplace continue protect people global business operating building employee resilience provide preventive healthcare protect health safety people market incident occur august business health start complement employee healthcare important focus refresh employee tragically die people end benefit establish market simplify standard help gsk boiler explosion site rixensaart belgium assess health need employee partnership prevention programme aim understand need safeguard addition support belgian authority site insight provide employee family people business environment investigation take step assessment target unprecedented access preventive healthcare global health wellbeing strategy check operation boiler gsk health need identify business service little cost implementation review set plan ensure design employee health plan come prioritise region access october sale employee india gsk employee access consistent year raise awareness leader preventive service unavailable limited travel business sadly die comprehensive health service continue local health programme particularly develop market motorcycle collide vehicle recognise leader health help people achieve healthy lifestyle service include immunisation wellbee gsk august explosion nearby chemical work major site cancer screening recommend multinational healthy workplace award warehouse damage building site country employee world health organization available global centre healthy workplace tianjin china employee suffer ensure core programme available employee family member minor injury allow staff return work hard address road exercise class discount fitness country place halfway check structural integrity site safety significant risk employee centre label healthy food option nutrition target implement globally monitor air quality toxic chemical particularly emerge market year education support quit smoking employee survey approximately launch driver safety programme india workforce take month implement country help employee protect global energy resilience reportable injury illness rate result show family programme combine online programme feedback indicate employee family member learn practical road safety activity focus energy resilience help service satisfaction rate driver motorcyclist roll employee improve personal resilience bangladesh cambodia indonesia wellbee time take country turkey pakistan vietnam employee survey agree place long period time see sufficient energy invest thing incremental increase awareness uptake see steady reduction matter work life service maintain high satisfaction reportable injury illness rate past year slight increase occur offer counsel confidential programme pilot ecuador ghana mainly large number employee assistance programme eap support nigeria romania semicircular lipoatrophy case treatable employee deal personal health wellbee expand middle east turkey condition associate localise pressure professional issue employees africa latin america early office furniture identify office access service continue launch india sri lanka bangladesh reportable injury illness rate brazil take comprehensive step hour work work overcome cultural barrier russia member commonwealth support impact prevent recurrence people reluctant use service independent statesgsk responsible business supplement people promote inclusion diversity diverse knowledge value diversity aim offer inclusive employee gender december partner working environment welcome people government disability confident campaign perspective experience male female total walk life survey raise disability awareness company work style proportion employee agree work remove barrier increase understand organisation diverse perspective total ensure people disability global workforce support value rise point right opportunity woman management position business help gender diversity membership business disability well meet need aim improve gender balance international social enterprise involve encourage woman join business svpvp global standard measure business patient consumer develop leader woman director disability performance represent recruit future manager world cultural ethnic diversity leader programme management total nationality represent corporate corporate executive team disability executive team board people board enhance attractiveness accessibility employ emerge market asia pacific accelerate difference programme business people disability japan represent workforce support development high perform priority gsk global disability council aim attract develop local talent female leader help advance gdc identify range opportunity market partner university career senior role increase gsk disability confidence offer opportunity business female manager begin make facility technology particular focus africa strategy build programme include individual group accessible addressing culture capability continent creation commitment continue promote inclusion coaching session internal external employee attitude disability new regional headquarters singapore diversity globally gsk coach support line manager set new disability confidence provide opportunity attract senior sponsor group dialogue session network provide forum employee develop talent asia provide platform male female find accessibility raise leader discuss career progression build strong pipeline important progress overview track awareness local initiative gsk share experience future leader represent diverse market launch online accessibility portal prompting action address genderrelate serve stay close patient need enable employee request issue nearly female participant world recruit people additional support adjustment achieve promotion country future leader work environment look roll take responsibility role graduate programme service country women leadership initiative business welcome student employee resource group support culture learning disability transition inclusion aim empower woman education employment project search achieve potential student complete member new group launch placement gsk begin africa europe singapore employment discussion december take place explore feasibility set project search gsk locationsgsk responsible business supplement people community volunteer create change people develop pulse volunteer partnership encourage employee world employee lend professional skill support local community offer pay pulse volunteer partnership skill support nonprofit partner help meet healthcare day year volunteer orange pulse volunteer partnership community challenge home abroad work day programme people volunteer employee use professional skill partner fulltime month time world support create sustainable change nonprofit world volunteer people challenge think differently recreation camp young girl india packing partner community serve time expertise develop leadership skill bring new school supply child usa avinash mohanty product group experience fresh idea gsk employee use orange day activity manager gsk india work support stem education case study year launch pulse clinton health access initiative inc chai scientist employee contribute million abuja nigeria develop comprehensive work project develop natural history worth skilled service nonprofit strategy increase treatment access museum molecular laboratory facility good suit partner country pulse child pneumonia conduct current future demand opportunity volunteer come country baseline assessment current practice half volunteer continue leverage global infrastructure key issue interview key outside usa ambassadors promote volunteering gsk stakeholder formulate plan programme start annual volunteer awareness week direct impact policy resource commitment extend volunteer total activity carry mobilisation market shaping opportunity bring positive change pulse programme aim create gsk site country include report assignment exceed community global health positive sustainable change partner town hall serbia farmer market finland expectation increase awareness provide individual development organisation community serve measure footprint day colombia importance patientfocuse survey nonprofit partner month information stand dubai uganda inspire find innovative volunteer complete insightful solution impact live assignment partner say gsk invite found partner progress overview progress volunteer contribution impact global collaboration time clinton health access last impact lead private sector aim mobilise initiative inc help increase corporate volunteer contribute global geographical reach partnership volunteer bring valuable goal sustainable development key stakeholder india skill support development collaboration nigerian government benefit business volunteer highperforming staff disease national interest different gsk return line manager member locate valuable experience transfer directly role gsk colleague agree experience month entirely pay bringing help develop skill performance new skill experience partnership save child begin gsk employee raise organisation valuable website hear million increase lead deep partnership people experience million match funding pulse volunteer gsk find save child organisation read pulse impact report partnership website simon wright head child survival save childrengsk responsible business supplement planet announce investment million enhance antibiotic manufacturing facility quality road singaporegsk responsible business supplement planet approach major global environmental challenge like climate highlight change deforestation exacerbate health carbon trust water issue undermine effort overcome gsk pharmaceutical company reduction water usage inequality world consequence hold carbon trust carbon standard hit water target year early current future generation likely cut carbon emission water severe poor particularly vulnerable carbon standard reduce water use new global goal sustainable operation globally reduce direct carbon emission development draw clear link health scope save environment million tonne year change environment lead high level read air pollution spread disease vector food insecurity undernutrition displacement reduce water year year supplier engagement force migration socioeconomic stress contribute health issue read sustainable supplier programme read award good supplier engagement global healthcare company ethical corporation responsible contribute tackling effect waste business awards environmental change work cdp result deliver health cause waste produce target carbon neutral value chain score climate change disclosure manufacturing site read ambitious goal reduce carbon water performance cdps ftse achieve zero waste landfill waste meantime year climate disclosure leadership index significant progress feedback ethical corporation judge work supplier gsk make contribution environmental challenge share knowledge comprehensive programme focus resource participation reduce scope carbon emission read caring climate initiative ceo ecodesk evaluation supplier water mandate businessle movement exchange workshop advance water stewardship sanitation carbon footprint supplier award gsk solve reduce value chain carbon problem make good footprint product ship progress area hold average versus influence judge appreciate gsk candid approachgsk responsible business supplement planet focus horlick take green leap india horlick bestknown brand instal effluent treatment nutritional supplement india plant rainwater harvesting system provide essential vitamin mineral enable water reuse disposed grow child safely cut water use help replenish groundwater restore discover lifecycle local water source analysis horlick second large carbon footprint product reason identify huge horlick factory opportunity reduced india nabha rajahmundry sonepat power coal carbon emission sonepat invest million project green tonne leap reduce carbon emission water use horlick factory example continue increase waste satyaprakash punia biomass buy replace coal fuel utility site energy manager sonepat india boiler construct new combine heat power plant rajahmundry fuel waste biomass plant improve efficiency capture heat power generation waste sonepat instal photovoltaic cell generate power solar energy investing efficient lead lighting site cut energy use project begin april cut carbon emission investment improve carbon water management horlick factoriesgsk responsible business supplement planet understanding value chain carbon footprint raw material gsk operation logistic use product disposal source raw material impact deliver medicine vaccine patient consumer disposal product gsk buy company lab factory office consumer health product product gsk patient consumer globe tonne coe annum tonne coe annum tonne coe annum tonne coe annum tonne coe annum use meter energy tonne coe annum tonne coe annum dose inhaler hfa process use tonne coe annum emission tonne coe annum product business travel tonne coe annum sale force tonne coe annum total estimate emission estimate tonne coe annum datum exclude novartis sitesgsk responsible business supplement planet aim carbon neutral working reduce performance reduce value chain raw material reduce operational emission carbon footprint product ship engage supplier crucial reduce emission entire scope million average versus emission raw material approach value chain extend tonne coe recognise ethical corporation continue growth sale cumulative saving million tonne coe responsible business award found access product ventolin propellantbase inhaler emit year achieve reduction datum collection collaboration recognition greenhouse gas administration people need continue focus energy efficiency use ecodesk online platform gather medication patient impact emission investment renewable energy datum carbon water waste scope continue research solution provide total energy use supplier represent approximately issue include change way million raw material begin decouple environmental manufacture reduce propellant impact business growth increase maintain efficacy patient supplier online access medicine volume tackle emission use medication supplier exchange platform share good medicine consumer health product remain challenge impact ability practice work directly vaccine send factory meet target cut absolute emission supplier identify way reduce high time value chain value chain carbon emission energy carbon footprint grow supplier environmental sustainability award commitment reduce overall carbon go flavouring supplier firmenich footprint comprehensive environmental programme carbon neutral value chain scope ghg emission scope ghg emission engagement supplier tonne coe tonne coe progress overview work target target gas fuel purchase material electricity steam product logistic propellant emission manufacture inhaler business travel air sale force travel propellant emission use inhaler emission use product reduce value chain carbon footprint exclude biogenic emission year accord disposal product product ship average current guidance account decrease emission estimate data datum exclude novartis site versus gsk responsible business supplement planet aim carbon neutral continue operation logistic disposal invest renewable energy partner logistic provider big carbon impact customer deforestation infrastructure convert lowemission reduce emission transportation disposal product come deforestation major contributor climate fuel improve energy efficiency cut product account inhaler small change take step ensure emission operation wind carbon footprint example encourage propellant greenhouse gas leave raw material woodbase packaging turbine instal site cork ireland supplier invest specialised trailer use encourage material palm oil source responsibly generate site electricity support storage different patient return working rainforest deliver saving million temperature product require different inhaler pharmacy send alliance map risk packaging supply tonne level refrigeration transport recycle complete chain analysis support enable cycle scheme work announce investment new source standard packaging vehicle road cut carbon healthcare trust combine million enhance antibiotic regularly assess supplier ensure emission tonne coe year health environmental message manufacture facility quality road meet standard route planning tool project like waste breath singapore addition million paper packaging material enable vehicle reduce journey times grampian region breathe well waste announce develop operation source responsibly trip efficient reduce brighton support patient roll process manufacture increase achieve carbon emission inhaler reduce need antibiotic amoxicillin enzyme technology source material supplier emergency care cut waste increase production paper mill certify reduce site carbon emission forest stewardship council move away chemical process biodiversity goal source paper eliminate chlorinate solvent biological material include genetic packaging gsk brand product organic waste resource commonly accord standard million investment combine heat tonne save annually development new medicine palm oil production damaging power chp boiler stevenage vaccine gsk directly involve effect important rainforest area expect save million year energy bioprospecting source purchase greenpalm certificate patient use cost reduce site carbon emission material derive natural covering tonne palm oil work carbon trust quantify bring total number chp product uphold nagoya protocol use horlick carbon footprint biggestselling boiler take care biological resource certify support production product different stage value chain obtain legitimately sustainable palm oil tonne patient use meter dose inhaler way intend palm oil buy equivalent mass carbonintensive activity sustainable palm oil produce portfolio aerosol propellant administer medication powerful gsk minimum condition virgin wood fibre specify material legal origin harvest greenhouse gas continue explore violation traditional civil right high conservation way reduce impact extend value forest forest convert plantation nonfor use access essential medicationgsk responsible business supplement planet reduce water impact well understanding performance operation meet target cut water use gsk laboratory manufacture site operational water use water use operation compare office million water million value chain focus year early reduce total value chain water investment watersaving footprint make major investment effort initiative past year help reduce site example big difference achieve reduction target site identify area nairobi site high water use locate kenya collect reuse water region water scarcity instal efficient system heat water site water meet commitment work consumption decrease expert ngo understand well reduce water impact entire value consumer use chain combine datum wwf water consumer patient need water use risk filter focus area water scarcity product make cup local water quality health social risk horlick brushing tooth help swallow target regulatory reputational risk identify tablet estimate consumer use commitment reduce water hotspot high water impact account water footprint impact value chain project emerge assessment water cleaning tooth continued promote turn tap raw material campaign sensodyne website water value printing logo sensodyne pronamel chain estimate million year progress overview progress toothpaste encourage people leave produce raw material water run brushing tooth agricultural produce milk sugar egg consumer use product potentially partner energy resource alter water quality quantity institute teri sustainable development ngo pharmaceutical product use india assess help reduce completely absorb broken water impact rural indian community body residue find way supply wheat barley milk environment particularly water course manufacture horlick pilot medicine excrete disposed approach direct supplier assess environmental risk associate extend work patient use product help ensure supply chain supplier rural community potential concentration environment level identify project address exceed safe level include test water conservation rainwater harvesting waste active pharmaceutical ingredient water treatment groundwater recharge ecotoxic property rehabilitation water body investigate publish data summary environmental option implement research risk assessment product datum exclude novartis sitesgsk responsible business supplement planet reduce waste change performance singapore quality road site partner packaging continue progress national university singapore want reduce waste manufacture halve commitment cut operational install onsite treatment facility hazardous operation work supplier operational waste hazardous nonhazardous waste use photooxidation break buying material sharing well year potentially harmful chemical organic practice sustainability supplier waste generate substance safely release exchange focused investment infrastructure technology shift environment process cut packaging ask supplier submit idea yield result produce tonne waste save tonne reduce paper packaging perception waste tonne waste coe eliminate need need consumer healthcare product previous year tonne represent incineration party potential resource total waste send landfill tonne waste quality road reduction tonne compare jurong site singapore fuel operational waste landfill low tonne jurong steam boiler generate million kwh thousand tonne operation energy cut site energy encourage site think differently cost waste view resource instead discard reuse recycled generate energy turn corner operational waste generate half manufacture thousand tonne site achieve zero waste landfill commitment reduce end site send operational waste waste landfill share good practice help site learn achievement progress overview track work goal example site east durham usa building insight share dungarvan site ireland install machine recycle fibre drum packaging storage transport save year site introduce innovative solution commitment cut waste streams facility sainte foy canada send egg waste vaccine production tonne sell compost secure regulatory approval louis site usa send manufacture waste compost instead landfill datum exclude novartis sitesgsk responsible business supplement datum summary health note well access medicine vaccine number dose rotarix vaccine donate gavi million cumulative value gsk medicine vaccine prescribe patient assistance programme million usd number patient reach patient assistance programme community investment total global community investment million strengthen healthcare system reinvestment ldc million healthcare worker partner train cumulative number people reach reinvestment programme million cumulative neglect tropical disease albendazole tablet help elimination million albendazole tablet help treat intestinal worm million total albendazole tablet donation total albendazole tablet donation million eradicate polio number dose oral polio vaccine deliver global polio eradication initiative million access antiretroviral treatment hiv number country viiv healthcare access programme operate number royaltyfree voluntary license available viiv healthcare product behaviour note compliance employee discipline policy violation employee dismiss agree leave company voluntarily document warning total number market promotional activity violation breach external code number contact speak channel clinical trial datum cumulative publicly available trial result summarie number study clinical study report post register number trial list datum available request number research team approve request access gsk trial datum gsk responsible business supplement datum summary behaviour note clinical research clinical quality assurance assessment audits investigator site conduct gsksponsore trial audits gsk process audits contract research organisation carry clinical trial behalf audits gsk local operating company involve clinical trial activity investigation suspect irregularity inspection gsk site regulatory authority anticounterfeite number report case confirm counterfeit number raid law enforcement authority number arrest law enforcement authority ensure quality manufacture supply number regulatory inspection pharmaceutical business number regulatory inspection vaccine business number regulatory inspection consumer healthcare business people note number fatality reportable incident lose time lose time reportable injury illness rate hour work reportable incident lose time reportable injury illness rate hour work talent leadership development total number coach assignment number graduate recruit number postgraduate recruit number apprentice recruit inclusion diversity percentage woman management total percentage employee emerge market asiapacific japan volunteer number employee complete pulse gsk responsible business supplement datum summary planet datum baseline notes carbon scope ghg emission tonne coe gas fuel electricity steam propellant emission manufacture inhaler sale force travel emission total scope ghg emission tonne coe purchase material estimate datum product logistic business travel air propellant emission use inhaler use product estimate data disposal product estimate datum total water water use operation million cubic metre waste total waste generate thousand tonne waste landfill thousand tonne compliance internal audits number environmental fine environmental remediation spend million detailed breakdown environmental fine available responsible business supplement fine discovery waste tank upper merrion site comply local regulation plus fine pay hamilton site failure submit risk management plan storage use chloroform responsibility remove pollution contaminant soil surface ground water facility previously disposal site waste management company usedgsk responsible business supplement read online publish detail topic report website health behaviour people planet clinical trial develop world gsk antibribery corruption hazardous chemical management climate change handbook develop world vaccine production gsk reach genetically modify microorganism technology transfer gsk antibribery corruption employee volunteer ozone depletion metereddose guideline party access medicine inhaler asthma gsk future leader programme develop country direct consumer marketing pharmaceutical environment prescription medicine gsk career site pandemic preparedness develop use ozone deplete substance country clone technology stem ancillary plant equipment cell research technology transfer capacity build green chemistry greener process develop country disclosure clinical trial information lab work health mother care welfare treatment animal detailed environment datum table child role transgenic animal assurance statement gsk briefing noncommunicable biomedical research disease develop world gsk response assurance statement use nonhuman primate nhps gsk position statement post discovery development medicine development agenda vaccine tiere pricing vaccine counterfeit healthcare product product donation pharmacovigilance noncommunicable disease criterion work public policy group code conduct clinical trial develop worldgsk responsible business supplement summary assurance statement bureau verita summary independent opinion recommendation statement independence impartiality assurance statement base assurance work carry competence report bureau verita limit engage evidence present bureau verita independent professional report performance annually gsk plc provide independent assurance scope work come service company specialise quality report commitment environment health safety ehs attention suggest factual information environment health safety social open transparent performance datum objective performance metric datum contain accountability year history business activity responsible business bureau verita work express opinion gsk ehs performance datum assurance team extensive experience cover annual report accuracy reliability ehs environmental social ethical health provide fair summary ehsrelated activity datum coverage datum provide summary finding safety information system process performance datum report relate gsk bureau verita code ethic ensure staff assurance statement find contain performance metric information member avoid conflict interest maintain global operation calendar year include detail scope work base establish collection high ethical standard business activity state methodology finding recommendation collation process deem datum environment health improvement free significant error omission bias gsk response assurance safety section independently please bureau verita finding verify bureau verita brand name summary scope methodology quality datum evidence site gsk establish process manage appear italic report assessment performance datum contain consolidated level see base ehs datum commit continue trade mark own andor ehs datum table associate date recently implement improve ultimate goal provide license gsk associate company datum management process involve datum management system eh central accurate ehs datum public detailed review integrity select support process guidance website continue work reporting standard dataset aggregation check index global reporting process corporate level implementation eh central improve data accuracy initiative guideline show element sample datum source gsk comprehensive effective improve emphasis incorporate recommendation cover report signatory site site choose represent submission data accuracy provide bureau verita global compact publish significant impact gsk operation refinement ehs report implementation new reporting system annual communication progress geographical spread inclusion complete ehs datum see improvement datum reporting demonstrate uphold principle commercial operation business area business datum interview senior ehs staff understand review support guidance procedure responsible business supplement feedback count gsk objective approach datum fully meet requirement new system site improve management welcome feedback collation management completion revise approach ehs programme responsible business performance detection anomaly log change continue work site improve report contact consolidate ehs dataset datum submission include provide comment csrcontactgskcom request explanation trend complete receive regular update progress timely fashion london february